Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies

@article{Taraz2017TranexamicAI,
  title={Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies},
  author={Mohammad Taraz and Somayeh Niknam and Amir Houshang Ehsani},
  journal={Dermatologic Therapy},
  year={2017},
  volume={30}
}
Melasma is a human melanogenesis dysfunction that results in localized, chronic acquired hyperpigmentation of the skin. It has a significant impact on appearance, causing psychosocial and emotional distress, and reducing the quality of life of the affected patients. Tranexamic acid (TA) is a plasmin inhibitor used to prevent abnormal fibrinolysis to reduce blood loss and exerts its effect by reversibly blocking lysine binding sites on plasminogen molecules, thus inhibiting plasminogen activator… 

Oral Tranexamic Acid for the Treatment of Melasma: A Review

Oral TXA is a safe and efficacious treatment for refractory melasma and should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy over a period of approximately 12 weeks and without contraindications to oral TXA.

Oral tranexamic acid for the treatment of melasma

  • F. Ali
  • Medicine
    Clinical and experimental dermatology
  • 2019
The majority of patients with clinical melasma treated with oral tranexamic acid showed clinical improvement, irrespective of whether concomitant topical therapies were used, and more favourable responses to TA treatment were seen in patients with no family history of melasma and in Patients with an older age of onset ofmelasma.

Oral Tranexamic Acid to Treat Melasma: A Literature Review

The published literature revealed that oral TA alone or concomitant with other therapeutic modalities safely and effectively treats melasma.

Tranexamic acid and platelet rich plasma in the treatment of melasma: efficacy and safety

  • Medicine
  • 2021
The approach with tranexamic acid administered both orally and topically, either alone or in association with other treatments, as well as platelet rich plasma (PRP) are interesting developments, and substances that act on the vascular component and mast cells are considered.

New oral and topical approaches for the treatment of melasma

Tranexamic Acid for Melasma: Evaluating the Various Formulations.

Different formulations of tranexamic acid for melasma are discussed, with oral formulations demonstrating the greatest, albeit temporary, improvement.

Evaluation of oral tranexamic acid in the treatment of melasma

Tranexamic acid (TA) is an inhibitor of plasmin, and it is a synthetic derivative of the amino acid lysine that reversibly blocks binding sites on the pl asminogen molecule, inhibiting the plAsminogen activator from converting plasmineogen to plasmini.

Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies.

This review aims to provide a summary of the more novel pathological findings and latest investigational therapies in melasma, an acquired hyperpigmentation disorder affecting females with darker skin types.

The optimal dose of oral tranexamic acid in melasma: A network meta-analysis

The optimal dose is 250 mg three times per day for 12 weeks, but 250 mg twice daily may be an acceptable option in poorly adherent patients, and the effects of different dosages will allow physicians to balance drug effects and medication adherence.

Formulation Development of Tranexamic Acid loaded Transethosomal Patch for Melasma

Findings showed that TEL may be a good carrier alternative for delivery of TXA into deeper layers, and hence good for treating melasma.

References

SHOWING 1-10 OF 39 REFERENCES

Treatment of Melasma With Oral Administration of Tranexamic Acid

Oral administration of tranexamic acid (TA) is an effective and safe therapy for the treatment of melasma and is graded into four levels: excellent, good, fair, and poor.

Topical tranexamic acid as a promising treatment for melasma

  • B. EbrahimiF. Naeini
  • Medicine
    Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
  • 2014
This study's results introduce the topical TA as an effective and safe medication for the treatment of melasma in Iranian women.

Localized Intradermal Microinjection of Tranexamic Acid for Treatment of Melasma in Asian Patients: A Preliminary Clinical Trial

  • Ji Ho LeeJong G Park Y. M. Park
  • Medicine
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • 2006
It is suggested that the intralesional localized microinjection of tranexamic acid (TA) can be used as a potentially new, effective, and safe therapeutic modality for the treatment of melasma.

Oral tranexamic acid in treatment of melasma in Pakistani population: a pilot study

Oral tranexamic acid is a safe and effective treatment in patients with melasma, and only few had oligomenorrhoea, palpitation and gastric upset.

Oral tranexamic acid for the treatment of melasma.

Addition of oral tranexamic acid provides rapid and sustained improvement in the treatment of melasma.

Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis.

Effect of tranexamic acid on melasma: a clinical trial with histological evaluation

Tranexamic acid (TXA), a plasmin inhibitor, is reported to improve melasma when injected locally and the effects of oral and topical TXA on melasma have not been well studied and the underlying mechanism remains unclear.

Melasma. Classification and treatment

From the many medications that have been used in the treatment of melasma, Hydroquinone alone at a concentration of 2‐5%, or in combination with tretinoin or tRETinoin and corticosteroids, is now the most widely used preparations.

Efficacy of Intradermal Injection of Tranexamic Acid, Topical Silymarin and Glycolic Acid Peeling in Treatment of Melasma: A Comparative Study

Silymarin cream was a novel, effective and safe treatment modality for melasma especially in epidermal and mixed types in Fitzpatrick skin phototype III, IV and V as it showed a significant improvement of melasma lesion.